Dr. Ghoneum is an internationally recognized immunologist who is an expert in the area of cancer immune therapy. He has published 90 articles and 130 abstracts, including 11 books in Japanese and in English related to cancer immunology. He holds 3 patents for inventing 3 biological response modifiers (BRMs) for the treatment of cancer. Dr. Ghoneum's contribution to immunotherapy is introducing and patenting several new non-toxic BRMs that activate different arms of the immune system such as NK, T, and dendritic cells and induce apoptosis of cancer cells. The most extensively studied of these BRMs is called arabinoxylan MGN-3. In the most recent human clinical trials, MGN-3 was demonstrated to enhance the anti-cancer activity of chemotherapy for the treatment of hepatocellular carcinoma (HCC). This is the first time that a natural BRM was shown to be effective for the treatment of HCC. Dr. Ghoenum has received several international awards from: The American Cancer Society (1993), Japan Functional Food Research Association (JAFRA) (2002), and The Filipino-Chinese Medical Society (2005). In 2007 he was nominated for the annual $1 million prestigious Gotham Prize in Cancer Research for his novel discovery of using baker's yeast for the treatment of cancer. He created a video to educate the public about a new cancer therapy. He had special accelerated promotion. He has been awarded numerous research grants from NIH-MBRS and major research institutions in Japan. He has been a reviewer for the NIH Study Section Member. He has been an organizer for annual workshops between the Japanese Immunology Society and Charles Drew University since 1990. He is a member of several Scientific Societies, including the American Association for Cancer Research (AACR). Dr. Ghoneum's goal is to expand MGN-3 immunotherapy for the treatment of cancer in multiple clinical trials, and in addition to emphasize the importance of his novel approach for using yeast therapy for the treatment of cancer metastasis.